Cerebrospinal fluid in Creutzfeldt–Jakob disease

Author(s):  
Inga Zerr ◽  
Saima Zafar ◽  
Matthias Schmitz ◽  
Franc Llorens
2005 ◽  
Vol 19 (5-6) ◽  
pp. 376-382 ◽  
Author(s):  
Lukas Cepek ◽  
Petra Steinacker ◽  
Brit Mollenhauer ◽  
Birgitt Wiese ◽  
Barbara Ciesielczyk ◽  
...  

Pharmacology ◽  
2017 ◽  
Vol 100 (5-6) ◽  
pp. 243-245 ◽  
Author(s):  
Christian Humpel ◽  
Thomas Benke

Clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by the analysis of Tau and 14-3-3 in the cerebrospinal fluid (CSF). In this short report, we report about a retrospective analysis performed on 2,296 routinely collected CSF samples, and 44 samples with a ratio of phosphoTau181/Tau <0.075 were selected. Analysis was performed with a novel 14-3-3 gamma CircuLex Elisa. We show that control levels were around 6,000 AU/mL and samples from Alzheimer patients were not different from those collected from healthy controls. Four cases of verified CJD had 14-3-3 CSF levels of >100,000 AU/mL, while 10 out of 12 suspected CJD samples with 14-3-3 CSF levels between 50,000-100,000 AU/mL were CJD positive. All samples with 14-3-3 levels between 15,000 and 50,000 AU/mL were not CJD cases but disorders with complex neuropathology. In conclusion, our data suggests that in CSF samples with a phospho-Tau-181/Tau ratio <0.075 CSF levels of 14-3-3 should be analyzed. Our data suggests a very high risk for CJD with 14-3-3 levels above 100,000 AU/mL and a probable diagnosis of CJD based on laboratory parameters above 50,000 AU/mL.


Aging ◽  
2016 ◽  
Vol 8 (11) ◽  
pp. 2927-2935 ◽  
Author(s):  
Matthias Schmitz ◽  
Franc Llorens ◽  
Alexander Pracht ◽  
Tobias Thom ◽  
Ângela Correia ◽  
...  

2010 ◽  
Vol 9 (11) ◽  
pp. 5646-5657 ◽  
Author(s):  
Joanna Gawinecka ◽  
Jana Dieks ◽  
Abdul R. Asif ◽  
Julie Carimalo ◽  
Uta Heinemann ◽  
...  

Neurology ◽  
2000 ◽  
Vol 54 (5) ◽  
pp. 1099-1102 ◽  
Author(s):  
M. Otto ◽  
H. Esselmann ◽  
W. Schulz-Schaeffer ◽  
M. Neumann ◽  
A. Schroter ◽  
...  

PROTEOMICS ◽  
2006 ◽  
Vol 6 (S1) ◽  
pp. S256-S261 ◽  
Author(s):  
Chiara Piubelli ◽  
Michele Fiorini ◽  
Gianluigi Zanusso ◽  
Alberto Milli ◽  
Elisa Fasoli ◽  
...  

2019 ◽  
Vol 76 (8) ◽  
pp. 969 ◽  
Author(s):  
Adam M. Staffaroni ◽  
Abigail O. Kramer ◽  
Megan Casey ◽  
Huicong Kang ◽  
Julio C. Rojas ◽  
...  

2020 ◽  
Vol 33 (13) ◽  
Author(s):  
Renato Oliveira ◽  
Marta Dias ◽  
Inês Brás Marques

Creutzfeldt-Jakob disease typically presents as rapidly progressive dementia. We describe the case of a 59-year-old male patient presenting with sudden onset of central facial palsy and dysarthria, followed by myoclonus of his left upper and lower limbs. Initial brain magnetic resonance showed hyperintensity of the right caudate and putamen on diffusion-weighted imaging and T2 sequences. Cerebrospinal fluid analysis showed increased protein count. The workup to investigate autoimmune, infectious and paraneoplastic causes was negative. Symptoms progressively worsened, with left hemiplegia, dysphagia, urinary incontinence, and, later, akinetic mutism. The follow-up brain magnetic resonance scan revealed hyperintensity of bilateral basal ganglia as well as cerebral cortical abnormalities on diffusion-weighted imaging. Electroencephalography showed periodic activity and tau protein levels in the cerebrospinal fluid were elevated. Genetic analysis showed mutation c-598G > A. The patient died four months later. We report a case of familial Creutzfeldt-Jakob disease with atypical clinical and radiological features, namely neurological focal signs with sudden onset, absence of significant cognitive impairment and unilateral radiological findings. With disease progression, characteristic clinical and radiological features led to the diagnosis.


2000 ◽  
Vol 102 (6) ◽  
pp. 385-387 ◽  
Author(s):  
I. Kohira ◽  
T. Tsuji ◽  
H. Ishizu ◽  
Y. Takao ◽  
A. Wake ◽  
...  

mBio ◽  
2015 ◽  
Vol 6 (1) ◽  
Author(s):  
Christina D. Orrú ◽  
Bradley R. Groveman ◽  
Andrew G. Hughson ◽  
Gianluigi Zanusso ◽  
Michael B. Coulthart ◽  
...  

ABSTRACT  Fast, definitive diagnosis of Creutzfeldt-Jakob disease (CJD) is important in assessing patient care options and transmission risks. Real-time quaking-induced conversion (RT-QuIC) assays of cerebrospinal fluid (CSF) and nasal-brushing specimens are valuable in distinguishing CJD from non-CJD conditions but have required 2.5 to 5 days. Here, an improved RT-QuIC assay is described which identified positive CSF samples within 4 to 14 h with better analytical sensitivity. Moreover, analysis of 11 CJD patients demonstrated that while 7 were RT-QuIC positive using the previous conditions, 10 were positive using the new assay. In these and further analyses, a total of 46 of 48 CSF samples from sporadic CJD patients were positive, while all 39 non-CJD patients were negative, giving 95.8% diagnostic sensitivity and 100% specificity. This second-generation RT-QuIC assay markedly improved the speed and sensitivity of detecting prion seeds in CSF specimens from CJD patients. This should enhance prospects for rapid and accurate ante mortem CJD diagnosis. IMPORTANCE A long-standing problem in dealing with various neurodegenerative protein misfolding diseases is early and accurate diagnosis. This issue is particularly important with human prion diseases, such as CJD, because prions are deadly, transmissible, and unusually resistant to decontamination. The recently developed RT-QuIC test allows for highly sensitive and specific detection of CJD in human cerebrospinal fluid and is being broadly implemented as a key diagnostic tool. However, as currently applied, RT-QuIC takes 2.5 to 5 days and misses 11 to 23% of CJD cases. Now, we have markedly improved RT-QuIC analysis of human CSF such that CJD and non-CJD patients can be discriminated in a matter of hours rather than days with enhanced sensitivity. These improvements should allow for much faster, more accurate, and practical testing for CJD. In broader terms, our study provides a prototype for tests for misfolded protein aggregates that cause many important amyloid diseases, such as Alzheimer’s, Parkinson’s, and tauopathies.


Sign in / Sign up

Export Citation Format

Share Document